Compass Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect two class III directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Richard S. Lindahl, M.B.A.

Compass Therapeutics, Inc.’s own tally for this item (“Elect Director: Richard S. Lindahl, M.B.A.”): 103,453,540 for, 18,368,143 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 19,066,033 for, 1,534,905 withheld, 31 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To elect two class III directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Thomas J. Schuetz, M.D., Ph.D.

Compass Therapeutics, Inc.’s own tally for this item (“Elect Director: Thomas J. Schuetz, M.D., Ph.D.”): 102,984,184 for, 18,837,499 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 18,916,921 for, 1,684,015 withheld, 33 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

Compass Therapeutics, Inc.’s own tally for this item (“3. Non-binding, Advisory Vote on the Compensation of our Named Executive Officers”): 117,963,684 for, 1,796,022 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders voted to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers, by the votes set forth in the table below:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 49 managers: 20,450,391 for, 150,573 against, 4 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 131 managers: 91,459,213 for, 980,594 against, 2,425,874 abstained, 274 not voted, 15,747 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 49 managers: 181,602 for, 3 abstained, 20,408,750 1 year, 10,377 3 year, 235 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 126 managers: 15,367 for, 380 against, 2,425,446 abstained, 274 not voted, 90,750,667 1 year, 83,369 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

Compass Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 137,896,097 for, 181,037 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of CohnReznick, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026, by the votes set forth in the table below:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 20,600,965 for, 4 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.